PYPD

Healthcare Biotechnology

PolyPid Ltd.

$5.19

+0.06 +1.17% today

Price History

Not enough data

Key Stats

Market Cap

105.42M

Avg Volume

190,684

EPS

-$1.44

52W High

$5.73

52W Low

$3.06

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-4.23

P/B Ratio

19.58

EV/EBITDA

-3.33

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(243.6%)

Return on Assets

(74.6%)

Liquidity & Leverage

Current Ratio

1.35

Quick Ratio

0.99

Debt / Equity

0.29

Total Cash

6.56M

Total Debt

1.57M

About

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.